FDA Reverses ODAC Opinion, Approves Gemzar For Ovarian Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA disagreed with the Oncologic Drugs Advisory Committee’s March determination that progression-free survival is not a valid endpoint for ovarian cancer.